Leucid Bio Reports Positive Progress in Phase I/IIa AERIAL Trial for Solid Tumor CAR-T Therapy

Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.

The findings mark progress for CAR-T therapies in solid tumors, a field long constrained by tumor microenvironment challenges. Leucid’s “lateral” CAR architecture—designed to improve T-cell persistence and tumor penetration—could represent a breakthrough in solid tumor immunotherapy. Full Phase II results are expected in the first half 2026.

Posted by MedCloudInsider Editors on 11/10/2025